Good pseudoaccommodation with MICS lens at one year

Article

The new MICS lens (Ioltech-Zeiss) is appropriate for the correction of intermediate vision in pseudophakia, according to Carlos Verges, Jorge Cazal and Marc Menezo of the Department of Ophthalmology, Institut Universitari Dexeus, Barcelona, Spain.

The new MICS lens (Ioltech-Zeiss) is appropriate for the correction of intermediate vision in pseudophakia, according to Carlos Verges, Jorge Cazal and Marc Menezo of the Department of Ophthalmology, Institut Universitari Dexeus, Barcelona, Spain.

The researchers presented the clinical results after one-year experience using the MICS lens. A total of 48 consecutive cataractous patients underwent MICS bimanual surgery and implantation of the lens using an incision of just 1.8 mm. The total diameter of the lens is just 12 mm allowing it to be positioned farther into the posterior plane than usual; 5.5 to 6 mm from the corneal endothelium at the nodal plane. The MTF, in the laboratory, was 92 changing to 80 with tilting conditions of 8º and decentration of 0.5 mm.

The results showed that, at one-year follow-up, 92% of subjects had an uncorrected distance visual acuity (UCDVA) of 20/25 and 96% a best corrected distance visual acuity (BCDVA) >20/25. 65% of patients achieved J3 with distance correction and 98% achieved J5. Two subjects required YAG laser for posterior capsule opacification (PCO) and two showed a folded haptic due to capsular retraction, not affecting vision or lens position. Three subjects reported glistening signs but vision was not affected.

Verges and his co-workers believe that the ability to position the lens at the level of the nodal planes combined with the lens' optical geometry allowing a pseudoaccommodative effect, makes the MICS lens appropriate for correct intermediate vision in pseudophakia.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.